About this trial
Extracellular vesicles (EVs) play a key role in cell-to-cell communication. They are small vesicles that contain rich molecular cargo. Recently, they have been proposed as biomarkers for clinical diagnostics. EVs include three classes: small EVs (exosomes), large EVs (microparticles), and apoptotic bodies. Platelet-derived EVs (PEVs) are the most abundant class in human blood and can actively participate in numerous physiological and pathological processes. The information about the role of platelet exosomes in cardiovascular disease and the effect of antiplatelet agents on their release and content is very limited.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
subjects without known pathologies
Disqualifiers
individuals with gastrointestinal diseases,
individuals with history of hepatic diseases,
individuals with history of urogenital diseases,
individuals with history of hematological diseases,
Trial population
subjects without known pathologies
Trial design
Other
Other
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
Characterization of exosomes released by activated platelet by Nanoparticle Tracking Analysis (NTA) and proteoma analysis
Characterization of exosomes released by activated platelet and exposed to platelet inhibitors by NTA and proteoma analysis
Secondary outcomes
Platelet exosome profile emerged by NTA and proteoma analysis will be related with the "biographical" and "anthropometric" data of the subjects.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Centro Cardiologico Monzino
Lead sponsor
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Collaborator